Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment
Author:
Affiliation:
1. Steno Diabetes Center; Gentofte Denmark
2. Rigshospitalet; Copenhagen Denmark
3. Aarhus University; Aarhus Denmark
4. University of Copenhagen; Copenhagen Denmark
Funder
Novo Nordisk
Publisher
Wiley
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/dme.12594/fullpdf
Reference37 articles.
1. The physiology of glucagon-like peptide 1;Holst;Physiol Rev,2007
2. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU);Marre;Diabet Med,2009
3. Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide;Vilsboll;Diabetes Obes Metab,2012
4. An overview of the pharmacokinetics, efficacy and safety of liraglutide;Bode;Diabetes Res Clin Pract,2012
5. Once-daily human GLP-1 analog liraglutide reduces systolic BP: a meta-analysis of 6 clinical trials;Fonseca;Diabetes,2009
Cited by 66 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function;Scientific Reports;2024-02-29
2. The concomitant use of sodium-glucose co-transporter 2 inhibitors improved the renal outcome of Japanese patients with type 2 diabetes treated with glucagon-like peptide 1 receptor agonists;Cardiovascular Endocrinology & Metabolism;2023-09-28
3. Albuminuria‐lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo‐controlled study;Diabetes, Obesity and Metabolism;2023-09-18
4. The mechanism of the transient increase of blood pressure caused by GLP-1 receptor agonist liraglutide in diabetic patients with severely impaired kidney function.;2023-07-18
5. Renoprotective effects of GLP-1 receptor agonists and SGLT-2 inhibitors—is hemodynamics the key point?;American Journal of Physiology-Cell Physiology;2023-07-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3